TodayLegal News

Verdict.News

Regulatory

Federal agency enforcement actions, rulemaking, and regulatory developments. Coverage of the SEC, FTC, CFPB, CFTC, OSHA, FDA, and other agencies shaping compliance and industry standards.

Regulatory
•4 min read

CFTC Secures $2M Restitution for Retirement Investors in Metals Fraud

The Commodity Futures Trading Commission obtained over $2 million in restitution for victims of a precious metals and foreign currency investment fraud that targeted retirement-planning investors. Robert L. Adams and his Oregon-based firm SimTradePro defrauded more than 100 customers out of $2.3 million through false fee claims and hidden trading losses.

•CFTC secured $2,072,986 restitution order against Robert L. Adams and SimTradePro for commodity pool fraud
•Over 100 victims, many retirement-planning investors, lost $2.3 million in fraudulent precious metals and currency schemes
AI-generated SummaryRead Article →
Regulatory
•4 min read

FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome

The FDA has approved Waskyra (etuvetidigene autotemcel), marking the first cell-based gene therapy treatment for Wiskott-Aldrich syndrome. This approval represents a significant milestone in treating the rare genetic immune disorder.

•FDA approves Waskyra as first cell-based gene therapy for Wiskott-Aldrich syndrome
•Treatment addresses rare X-linked immunodeficiency disorder primarily affecting males
AI-generated SummaryRead Article →
Regulatory
•4 min read

FDA Approves First Drug Under New Priority Voucher Program

The FDA approved Augmentin XR as the first drug under its new Commissioner's National Priority Voucher pilot program. This milestone marks a new regulatory pathway designed to strengthen domestic antibiotic manufacturing capacity.

•Augmentin XR becomes first drug approved under FDA's new Commissioner's National Priority Voucher pilot program
•Program aims to strengthen domestic antibiotic manufacturing and reduce foreign supply dependence
AI-generated SummaryRead Article →
Regulatory
•4 min read

FTC Warns 13 Property Management Software Companies Over Hidden Rental Fees

The Federal Trade Commission issued warning letters to 13 property management software providers nationwide, alleging they may be violating federal law by preventing rental property managers from displaying complete pricing information to consumers. The enforcement action follows the FTC's recent $24 million settlement with Greystar for deceptive pricing practices.

•FTC sent warning letters to 13 unnamed property management software companies for potentially hindering accurate rental pricing disclosure
•Software providers allegedly prevent inclusion of mandatory fees in advertised rental prices, harming consumer decision-making
AI-generated SummaryRead Article →
Regulatory
•4 min read

FTC Returns $27.6M to Victims of Unauthorized Billing Scams

The Federal Trade Commission is distributing more than $27.6 million to over 1.2 million consumers who were victims of unauthorized billing schemes involving CBD, Keto, and other health products. The settlement stems from a case against several companies that enrolled consumers in recurring billing plans without consent.

•FTC distributing $27.6 million to 1,215,337 consumers victimized by unauthorized billing schemes
•Five companies permanently banned from negative option marketing and required to forfeit assets
AI-generated SummaryRead Article →
Regulatory
•4 min read

FDA Approves First Cellular Therapy for Severe Aplastic Anemia

The FDA has approved Omisirge (omidubicel-onlv), marking the first hematopoietic stem cell transplant therapy specifically designed to treat patients with severe aplastic anemia. This approval represents a significant regulatory milestone in cellular therapy development.

•First FDA-approved cellular therapy specifically for severe aplastic anemia treatment
•Omisirge utilizes hematopoietic stem cell transplant technology to restore blood cell production
AI-generated SummaryRead Article →
Regulatory
•4 min read

7-Eleven Pays Record $4.5 Million FTC Penalty for Consent Order Violation

7-Eleven will pay a record $4.5 million to settle Federal Trade Commission allegations that it violated a 2018 consent order by acquiring a Florida fuel outlet without required prior notice. The penalty represents the largest civil fine ever collected for a prior-notice violation and the biggest negotiated settlement in FTC Bureau of Competition history.

•$4.5 million penalty is largest ever for FTC prior-notice violation and biggest negotiated order violation settlement
•7-Eleven acquired St. Petersburg, Florida fuel outlet without notifying FTC as required under 2018 consent order
AI-generated SummaryRead Article →
Regulatory
•2 min read

FTC Rejects SpyFone CEO's Bid to Overturn Stalkerware Ban

The Federal Trade Commission denied a petition from SpyFone CEO Scott Zuckerman to vacate or modify a 2021 order that permanently bans him from the surveillance app business. The Commission found Zuckerman failed to demonstrate sufficient changed circumstances to justify reopening the consent order.

•FTC unanimously rejected Zuckerman's petition to overturn the 2021 ban on surveillance app businesses
•Original case involved SpyFone apps that secretly monitored devices and required disabling security protections
AI-generated SummaryRead Article →
Regulatory
•4 min read

FDA Launches TEMPO Pilot to Expand Digital Health Device Access

The Food and Drug Administration announced the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program, a first-of-its-kind voluntary initiative designed to expand patient access to digital health devices for chronic disease management while maintaining safety protections.

•TEMPO is the FDA's first pilot program specifically designed to expand access to digital health devices for chronic disease management
•The voluntary initiative aims to balance increased patient access with maintaining safety protections and regulatory oversight
AI-generated SummaryRead Article →
Regulatory
•4 min read

Aya Healthcare Drops Cross Country Merger After FTC Antitrust Concerns

Aya Healthcare terminated its proposed acquisition of Cross Country Healthcare after the Federal Trade Commission raised significant competitive concerns. The FTC warned the merger would eliminate competition between two major healthcare staffing firms and potentially increase costs for hospitals and patients.

•FTC identified competitive concerns that would eliminate head-to-head competition between two largest healthcare staffing firms
•Merger termination protects options for thousands of healthcare workers and prevents hospital cost increases
AI-generated SummaryRead Article →